Molecular Subtype
Chronic Myeloid Leukemia, BCR-ABL1 Positive
CI-CAN-00002365CMLExplore in graph →
Hematologic102 active trials3 approved drugs320 evidence items
- NCIt
- C3174
- OncoTree
- CMLBCRABL1
- DOID
- 0081088
- DOID
- 8552
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00002365CMLExplore in graph →
Clinical trials
649 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (104)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05433532 | Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients | completed | Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 25, 2024 | clinicaltrials |
| NCT03481868 | EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors(EPIK) | unknown | N/A | 160 | University Hospital, Clermont-FerrandOTHER | 1 | Apr 9, 2024 |
| clinicaltrials |
| NCT05963061 | Chronic Myeloid Leukemia (CML) Real-Life Database | recruiting | — | 3,500 | University Hospital, Clermont-FerrandOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT04666025 | SARS-CoV-2 Donor-Recipient Immunity Transfer | completed | — | 26 | City of Hope Medical CenterOTHER | 1 | Apr 8, 2024 | clinicaltrials |
| NCT03959241 | TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)(1703/1801) | completed | Phase 3 | 431 | Medical College of WisconsinOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT01588015 | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant | completed | Phase 1 | 36 | City of Hope Medical CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT05421091 | Special Drug Use-results Surveillance of Scemblix Tablets | completed | — | 550 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 27, 2024 | clinicaltrials |
| NCT04793399 | Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients | terminated | Phase 1 / Phase 2 | 9 | Fundacion Espanola para la Curacion de la Leucemia Mieloide CronicaOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT02734823 | Long Term Effects of Tyrosine Kinase Inhibitor Therapy on Ovarian Reserve and Fertility in Patients With Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumor | withdrawn | — | 0 | University of Southern CaliforniaOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT01858740 | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children | completed | Phase 2 | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | terminated | Phase 1 | 2 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT04384848 | The EMPATHY Pilot Study | completed | N/A | 94 | Northwestern UniversityOTHER | 2 | Mar 4, 2024 | clinicaltrials |
| NCT02222272 | Effect of 2nd Gen TKI in CML | completed | — | 432 | European Society for Blood and Marrow TransplantationNETWORK | 9 | Feb 20, 2024 | clinicaltrials |
| NCT06266975 | Chronic Kidney Disease Patient in Chronic Myloied Leukemia | not yet recruiting | — | 40 | Sahar Mohammed GadOTHER | 0 | Feb 20, 2024 | clinicaltrials |
| NCT03996096 | Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients: Observatory Trial Studying the Biological Factors.(KIWIS) | completed | — | 50 | University Hospital, CaenOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT01735955 | Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study | completed | Phase 4 | 57 | Novartis PharmaceuticalsINDUSTRY | 16 | Feb 8, 2024 | clinicaltrials |
| NCT02057185 | Occupational Status and Hematological Disease(EMATO0113) | completed | — | 141 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06233890 | The Analysis of Fatigue on Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia(TIRE) | unknown | — | 50 | Imperial College Healthcare NHS TrustOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT01904136 | Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 54 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT06211166 | Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction | recruiting | — | 300 | Peking University People's HospitalOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT01281735 | International Chronic Myeloid Leukemia Pediatric Study(ICMLPed) | recruiting | — | 750 | Poitiers University HospitalOTHER | 20 | Jan 17, 2024 | clinicaltrials |
| NCT03128359 | High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant | completed | Phase 2 | 38 | City of Hope Medical CenterOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05201183 | A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Naoyuki G. Saito, M.D., Ph.D.OTHER | 1 | Dec 11, 2023 | clinicaltrials |
| NCT04663100 | Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence | unknown | N/A | 30 | University of TennesseeOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT00540995 | Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer | terminated | Phase 1 / Phase 2 | 25 | City of Hope Medical CenterOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT03193281 | KISS Study: Kinase Inhibition With Sprycel Start up(KISS) | unknown | Phase 2 | 91 | University of Auckland, New ZealandOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT06148493 | Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United States Using a Large Claims Database | completed | — | 425 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 28, 2023 | clinicaltrials |
| NCT03455517 | Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia(VeRitAs) | completed | Phase 2 | 77 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT06121765 | Metabolic Alternation and Clinicohematological Characteristic in Chronic Phase CML in Patient Treated With TKI | unknown | — | 45 | Assiut UniversityOTHER | 0 | Nov 8, 2023 | clinicaltrials |
| NCT01823198 | Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies | completed | Phase 1 / Phase 2 | 63 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT04739826 | Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia | unknown | — | 491 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Nov 3, 2023 | clinicaltrials |
| NCT03262974 | Effect of Pharmacogenetics on Imatinib Plasma Level and Response | completed | — | 60 | Assiut UniversityOTHER | 1 | Oct 27, 2023 | clinicaltrials |
| NCT03096782 | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma | completed | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT02546375 | A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands | completed | — | 87 | PfizerINDUSTRY | 1 | Oct 3, 2023 | clinicaltrials |
| NCT02767388 | Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery(Chemobrain) | completed | — | 45 | University of NebraskaOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT04048564 | Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®) | completed | — | 120 | Incyte BioSciences FranceINDUSTRY | 1 | Sep 28, 2023 | clinicaltrials |
| NCT01428635 | Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy | completed | Phase 2 / Phase 3 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT06042660 | Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis | completed | — | 527 | Polish Adult Leukemia GroupOTHER | 0 | Sep 18, 2023 | clinicaltrials |
| NCT01044745 | Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer | terminated | Phase 2 | 20 | University of NebraskaOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT05734053 | Nilotinib for Patients With Chronic Myeloid Leukemia in First Line and Any Subsequent Line(NOFRETETE) | completed | — | 222 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 21, 2023 | clinicaltrials |
| NCT04645706 | Innate T Cells and TKI Discontinuation(TIBIOP-LMC) | active not recruiting | — | 92 | Poitiers University HospitalOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03267186 | Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant | completed | Phase 2 | 8 | Andrew RezvaniOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT02311998 | Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML | completed | Phase 1 / Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT05926128 | Study of Treatment Free Remission in Patients With Chronic Myeloid Leukemia in Chronic Phase(AST) | unknown | N/A | 75 | FundaleuOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT01572662 | Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning | completed | Phase 2 | 201 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT01593254 | Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib(DASCERN) | completed | Phase 2 | 262 | Bristol-Myers SquibbINDUSTRY | 15 | Jun 22, 2023 | clinicaltrials |
| NCT05893836 | Real-World Disease Management and Outcomes in Chronic Myeloid Leukaemia | completed | — | 555 | Novartis PharmaceuticalsINDUSTRY | 1 | Jun 8, 2023 | clinicaltrials |
| NCT01657604 | TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study(TIGER) | completed | Phase 3 | 717 | University of JenaOTHER | 3 | May 10, 2023 | clinicaltrials |
| NCT02890784 | Dasatinib Holiday for Improved Tolerability(DasaHIT) | completed | Phase 3 | 291 | University of JenaOTHER | 1 | May 10, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Apr 25, 2024source: clinicaltrials